Develops next‑generation immune‑cell‑targeting biologics and antibody–drug conjugates using proprietary molecular‑glue payloads. Aims to expand ADC therapeutic window, overcome resistance mechanisms, and unlock new target space to benefit patients with high unmet medical need.